Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 235

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 235
---
 percentage of voting power of the Enfusion Common Stock and Enfusion Class B Common Stock 
 voting together as a single class.                                                                   |

167

| (3) | Includes (a) 19,467 shares of Enfusion Common Stock directly held by Mr. Movchan, (b) 24,914 shares of                                                                                                                                       
 Enfusion Common Stock underlying Enfusion Stock Options directly held by Mr. Movchan that are or will become exercisable within 60 days of February 5, 2025, (c) 37,426 shares of Enfusion Common Stock issuable upon the settlement of RSUs 
 releasable within 60 days of February 5, 2025, (d) 1,151,818 shares of Enfusion Common Stock directly held by CSL Tech Holdings, LLC (“CSL Tech”) and (e) 12,616,365 shares of Enfusion Common Stock that CSL Tech has the right to          
 acquire upon the exchange of Common Units directly held by CSL Tech. Mr. Movchan and his spouse may be deemed to have shared voting and dispositive power over such 1,151,818 shares of Enfusion Common Stock directly held by CSL Tech and  
 12,616,365 shares of Enfusion Common Stock that CSL Tech has the right to acquire upon the exchange of Common Units.                                                                                                                         |

| (4) | Includes 36,044 shares of Enfusion Common Stock issuable upon the settlement of RSUs releasable within 60 days 
 of February 5, 2025.                                                                                           |

| (5) | Includes (a) 12,896 shares of Enfusion Common Stock underlying stock options directly held by Ms. Bastone                                                                                                
 that are or will become exercisable within 60 days of February 5, 2025 and (b) 8,651 shares of Enfusion Common Stock issuable upon the settlement of RSUs releasable within 60 days of February 5, 2025. |

| (6) | Consists of (a) 31,297,606 shares of Enfusion Common Stock directly held by FTV IV, L.P. (“FTV Fund                                                                                                                                          
 IV”) and (b) 1,142,857 shares of Enfusion Common Stock directly held by FTV Investment Holdings, L.P. (“FTV Holdings”), as reflected in Note 9 below. Mr. Bernstein, a member of our Board, is the managing partner of FTV                   
 Capital and shares voting